An aphrodisiac is a substance that increases sexual desire. The name comes from the Greek ἀφροδισιακόν, aphrodisiakon, i.e. "sexual, aphrodisiac", from aphrodisios, i.e. "pertaining to Aphrodite", the Greekgoddess of love. Throughout history, many foods, drinks, and behaviors have had a reputation for making sex more attainable and/or pleasurable. However, from a historical and scientific standpoint, the alleged results may have been mainly due to mere belief by their users that they would be effective (placebo effect).
Some purported aphrodisiacs gain their reputation from the principles of sympathetic magic.
Some compounds that activate the melanocortin receptorsMC3-R and MC4-R in the brain are effective aphrodisiacs. One compound from this class, bremelanotide, formerly known as PT-141, is undergoing clinical trials for the treatment of sexual arousal disorder and erectile dysfunction. It is intended for both men and women. Preliminary results have proven the efficacy of this drug, however development was suspended due to a side effect of increased blood pressure observed in a small number of trial subjects who administered the drug intra-nasally. On 12 August 2009, Palatin, the company developing the drug, announced positive results (none of the previous heightened blood pressure effects were observed) of a phase I clinical study where trial subjects were instead administered the drug subcutaneously. Palatin is concurrently developing a related compound they call PL-6983.
As per a new study, crocin has demonstrated the properties of an aphrodisiac in rats.
Phenylethylamine (PEA) present in many food compounds as well as the human body is an aphrodisiac; however, this compound is quickly degraded by the enzyme MAO-B and so it is unlikely that any significant concentrations would reach the brain without a monoamine oxidase inhibitor. Amphetamine and methamphetamine, both phenethylamines, at high doses have been associated with hyperarousal, hypersexuality, and frequent or prolonged erections, although libido is reduced for some. Methamphetamine is such an effective aphrodisiac that an entire sub-culture known as party and play is based around sex and methamphetamine use.
Libido is clearly linked to levels of sex hormones, particularly testosterone. When a reduced sex drive occurs in individuals with relatively low levels of testosterone (e.g., post-menopausal women or men over age 60), testosterone supplements will often increase libido. Approaches using a number of precursors intended to raise testosterone levels have been effective in older males, but have not fared well when tested on other groups.
Yohimbine is the main alkaloid of Yohimbe. Yohimbe, but not Yohimbine, is often popularly referred to as a "weak MAO inhibitor." Pharmaceutical preparations of yohimbine do not indicate that the drug, which is approved in the US for treatment of impotence (under such brand names as Yocon,Yohimex, Aphrodyne and Viritab), is an MAO inhibitor. Its main action is as an alpha-adrenergicantagonist, by which yohimbine may increase genital bloodflow and both sexual sensitivity and excitation in some people. Preparations of yohimbe bark are available over-the-counter and should be used with caution. The unrefined yohimbe bark contains several active alkaloids besides yohimbine. Side effects can include rapid pulse, sweating, and anxiety reactions in susceptible people. Pharmaceutical preparations of yohimbine can also produce these side effects at higher doses, but are available in standardized doses which allow the patient to dose in a controlled fashion. Some patients report a cumulative prosexual effect using the drug over time.
The libido-enhancing effects of dopamine agonists prescribed for other purposes has led to the development of a number of more selective compounds such as flibanserin, ABT-670 and PF-219,061, which have been developed specifically for the treatment of sexual dysfunction disorders, although none of them have yet passed clinical trials.
Some psychoactive substances such as alcohol, cannabis,[not in citation given]methaqualone, GHB and MDMA can increase libido and sexual desire. However these drugs are not aphrodisiacs in the strict sense of the definition, as they do not consistently produce aphrodisiac effects as their main action and often actually impair function (hence, Shakespeare's famed statement that alcohol "provokes the desire, but it takes away the performance"). Nonetheless, these drugs are sometimes used to increase sexualpleasure and to reduce sexual inhibition. Anti-erectile dysfunction drugs, such as Viagra and Levitra, are not considered aphrodisiacs because they do not have any direct effect on the libido, although increased ability to attain an erection may be interpreted as increased sexual arousal by users of these drugs.
This section needs more medical references for verification or relies too heavily on primary sources. Please review the contents of the section and add the appropriate references if you can. Unsourced or poorly sourced material may be removed.(December 2012)
^ abSan Francisco Meth Zombies (TV documentary). National Geographic Channel. August 2013. ASINB00EHAOBAO.|accessdate= requires |url= (help)
^R. Shabsigh (1997). "The effects of testosterone on the cavernous tissue and erectile function". World J. Urol15 (1): 21. doi:10.1007/BF01275152. PMID9066090.|accessdate= requires |url= (help)
^Goldstat, Rebecca; Esther Briganti; Jane Tran; Rory Wolfe; Susan R. Davis (September 2003). "Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women.". Menopause10 (5): 390–8. doi:10.1097/01.GME.0000060256.03945.20. PMID14501599.|accessdate= requires |url= (help)
^Gray, P.B.; A.B. Singh, L.J. Woodhouse, T.W. Storer, R. Casaburi, J. Dzekov, C. Dzekov, I. Sinha-Hikim, S. Bhasin (2005). "Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men". J Clin Endocrinol Metab.90 (7): 3838–46. doi:10.1210/jc.2005-0247. PMID15827094.Cite uses deprecated parameters (help);|accessdate= requires |url= (help)
^Brown, G.A.; Vukovich MD; Martini ER; Kohut ML; Franke WD; Jackson DA; King DS. (2001). "Effects of androstenedione-herbal supplementation on serum sex hormone concentrations in 30- to 59-year-old men". Int J Vitam Nutr Res71 (5): 293–301. doi:10.1024/0300-9818.104.22.1683. PMID11725694.|accessdate= requires |url= (help)
^Brown, G.A.; Vukovich MD; Reifenrath TA; Uhl NL; Parsons KA; Sharp RL; King DS. (2000). "Effects of anabolic precursors on serum testosterone concentrations and adaptations to resistance training in young men.". Int J Sport Nutr Exerc Metab10 (3): 340–59. PMID10997957.|accessdate= requires |url= (help)
^Ang, H.H.; M.K. Sim (1997). "Eurycoma longifolia Jack enhances libido in sexually experienced male rats.". Exp Anim.46 (4): 287–90. doi:10.1538/expanim.46.287. PMID9353636.|accessdate= requires |url= (help)
^Ang, H.H.; Lee KL; Kiyoshi M. (2004). "Sexual arousal in sexually sluggish old male rats after oral administration of Eurycoma longifolia Jack.". J Basic Clin Physiol Pharmacol.15 (3–4): 303–9. doi:10.1515/JBCPP.2004.15.3-4.303. PMID15803965.|accessdate= requires |url= (help)
^McKay, D. (2004). "Nutrients and botanicals for erectile dysfunction: examining the evidence.". Altern Med Rev.9 (1): 4–16. PMID15005641.|accessdate= requires |url= (help)
^Gauthaman, K.; A.P. Ganesan, R.N. Prasad. (2003). "Sexual effects of puncturevine (Tribulus terrestris) extract (protodioscin): an evaluation using a rat model.". J Altern Complement Med.9 (2): 257. doi:10.1089/10755530360623374. PMID12804079.Cite uses deprecated parameters (help);|accessdate= requires |url= (help)
^Gauthaman, K.; P.G. Adaikan, R.N. Prasad. (2002). "Aphrodisiac properties of Tribulus Terrestris extract (Protodioscin) in normal and castrated rats.". Life Sci.71 (12): 1385–96. doi:10.1016/S0024-3205(02)01858-1. PMID12127159.Cite uses deprecated parameters (help);|accessdate= requires |url= (help)
^Neychev, V.K.; V.I. Mitev (2005). "The aphrodisiac herb Tribulus terrestris does not influence androgen production in young men.". J Ethnopharmacol.101 (1–3): 319–23. doi:10.1016/j.jep.2005.05.017. PMID15994038.|accessdate= requires |url= (help)